Taiwan News

Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs

ATG-207 is a globally first-in-class dual-function biologic being developed for the treatment of T cell–mediated autoimmune diseases. The Company plans to present the preclinical data for ATG-207 for ...
Seeking Alpha

Innovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the ESMO Asia Congress 2024

SAN FRANCISCO and SUZHOU, China, Dec. 8, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
Morningstar

Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented preclinical data showing its proprietary ...
Morningstar

Daiichi Sankyo Presents New Data in Small Cell Lung Cancer and Updates Across ADC Portfolio Highlighting Progress in Creating New Standards of Care for Patients with Lung ...

Late-breaking data from IDeate-Lung01 phase 2 trial demonstrate potential of ifinatamab deruxtecan to become first-in-class B7-H3 directed ADC for pretreated extensive-stage small cell lung cancer ...
KTLA

Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with ...

The spliceosome targeting payload, PH1, demonstrates the ability to induce both cancer cell cytotoxicity and activation of anti-tumor immunity through multiple mechanisms Treatment with a ...